资源描述
Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Systemic,Treatment of Colorectal Cancer in Metastatic&Adjuvant Settings Yesterday,Today,and Tomorrow,系统性,大肠癌治疗,:,过去,现在和将来,消化肿瘤科主任,Adenoma to Carcinoma Pathway,Adenoma,Normal,Cancer,Normal epithelium,Dysplastic ACF,Early adenoma,Late adenoma,Carcinoma,Metastatic carcinoma,5 q LOH*,(APC/-catenin),?K-ras,?K-ras,18 q LOH,DCC/SMAD4/SMAD2,17 q LOH,MMR activation,ACF=aberrant crypt foci;MMR=mismatch repair.,Stage Systems:Terminology vs.Contents(,概念与内涵,);Populations vs.Individuals(,群体与个体,),Stage I,Stage II,Stage III,Stage IV,Disease development,Staging,T1,N0,M0,T2,N0,M0,A:,T3,N0,M0,B:T4a,N0,M0,C:T4b,N0,M0,A:,T1-2,N1a-c;,T1,N2a;,B:,T3-4a,N2a,T2-3,N2a;,T1-2,N2b,C:,T4a,N2a;,T3-4a,N2b;,T4b,N1-2,M1:Distal Metastasis,M1a:,One organ site(liver,lung,ovary,nonregional node,),M1b:,one organ/site or Peritoneum,Definition,Invades submucosa(T1)/muscular propria(T2),T3:,Invades through muscularis propria into pericolorectal tissues,T4a:,penetrates to the surface of the visceral peritoneum,T4b:,invades or is adherent to other organs or structures,N1:,metastasis in 1-3LN,N1a:,1 LN,N1b,:2-3LN,N1c,:,deposits in the subserosa,mesentery,oro nonperitonealized pericolic tissue w/o LN,N2:,4LN,N2a,:4-6 LN,N2b:,7 LN,Involves distant metastases,Usual treatment,Surgery,Surgery chemotherapy,Surgery+chemotherapy,Chemotherapy surgery,SEER Colon Cancer 1973-2005(USA)N=28,491,0,1 yr.,2 yr,3 yr,4 yr,5 yr,I,91.4,87.0,82.6,78.2,74.0,IIA,89.9,83.4,77.8,72.0,68.5,IIB,85.4,77.8,69.1,62.9,58.6,IIC,66.0,52.5,45.3,41.5,37.3,IIIA,98.3,88.0,83.6,79.1,73.1,IIIB,83.4,70.8,59.3,51.7,46.3,IIIC,71.9,50.3,39.0,32.9,28.0,IV,39.9,19.7,11.3,7.6,5.7,5-Fluorouracil(5-FU),Advances in the Treatment of Colorectal Cancer,1980,1985,1990,1995,2000,2005,Therapeutic concepts,Palliative CT,Adjuvant CT,Pre-operativeCT,Capecitabine,Oxaliplatin,Cetuximab,Bevacizumab,Irinotecan,5-FU,Panitumumab,Targeted therapies,KRas WT/MT,Braf,2008,Management of MCRC:An Evolving Treatment Algorithm,Diagnosis of MCRC,Resectable,Unresectable,Adjuvant therapy,Surgery,Neoadjuvant/,preoperative therapy,First-line,Second-line,Third-line,Borderline/,potentially,resectable,Fourth-line,Treatment continuum,0.0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,0,6,12,18,24,30,36,42,Months,Irinotecan/5-FU/LV(N=231),5-,FU/LV(N=226),IFL,P,=0.042*,Probability,*,log-rank test,14.8,mo,12.6,mo,FOLFIRI,*,Medians Log-rank test,p0.032,CPT-11/5-FU/LV(N=198),5-,FU/LV(N=187),17.4,mo*,14.1,mo*,Months,Probability,0.0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,0,6,12,18,24,30,600,600,FOLFOX4,B 400,mFOLFOX6,2400,FOLFOX7,FOLFOX Regimens,200,B 400,85,200,400,85,2400-3000,400,130,B 400,mFOLFOX7,400,100,3000,FOLFOX6,400,100,2400-3000,B 400,CPT-11 180 mg/m,2,+simplified LV5FU,Randomized,multicentric,open-label,prospective,phase III trial,FOLFIRI,FOLFOX6,L-OHP 100 mg/m,2,IV,+simplified LV5FU,R,FOLFOX6,FOLFIRI,until progression,until,progression,until,progression,until progression,Arm A,Arm B,FOLFIRI vs.FOLFOX,OPTIMOX-1,Tournigand et al,JCO 2006,6x,FOLFOX7,-12x sLV5FU2-6x,FOLFOX7,FOLFOX4,620 pts,R,Cum.Oxali,780,1560,(%),FOLFOX4,FOLFOX7,RR58.558.3,PFS9.08.7,DDC9.010.6,OS19.321.2,G3/4 NTox17.913.3,Primary endpoint,OPTIMOX Studies,OPTIMOX-1,FOLFOX 4 until TF,FOLFOX 7,FOLFOX 7,sLV5FU2,OPTIMOX-2,mFOLFOX 7,mFOLFOX 7,sLV5FU2,mFOLFOX 7,mFOLFOX 7,CFI,CFI:Chemotherapy Free Interval,Phase II OPTIMOX2 Trial:,Study Design,OPTIMOX1:maintenance therapy,mFOLFOX7 x 6 cycles,sLV5FU2 until baseline progression,FOLFOX7 reintroduction,OPTIMOX2:chemotherapy-free interval,mFOLFOX7 x 6 cycles,No maintenance until progression,FOLFOX7 reintroduction,RANDOMI,ZAT,ION,mFOLFOX7,LV 400,5-FU 3000,Oxali 100,H0 H2 H24 H48,sLV5FU2,LV 400,5-FU 3000,H0 H2 H24 H48,5FUb 400,1 cycle=14 days,Dose=mg/m,2,Phase III Trial Bevacizumab in First-Line MCRC(AVF2107g),*,Patients receiving Avastin could continue therapy past disease progression in combination with second-line therapy.,Previously untreated MCRC,(n=923),IFL+placebo,(n=411),5-FU/LV+bevacizumab,(5 mg/kg,q2w)(n=110),IFL+Bevacizumab,(5 mg/kg,q2w)(n=402),Primary endpoint:Survival,Phase III Trial of Bevacizumab in First-Line MCRC:Survival,Error bars represent 95%confidence intervals.,Percent surviving,Months,20,0,12,18,30,0,80,100,40,60,Treatment Group,IFL+placebo(n=411),IFL+Avastin(n=402),24,6,Median survival:15.6 vs 20.3 mo,P,0.001,E3200:High-dose BEV+FOLFOX4:Study Design,RANDOMIZE,FOLFOX4,+Bevacizumab,(BEV 10 mg/kg q2 wk),(n=289),N=822,Previously treated mCRC,FOLFOX4,(n=290),Bevacizumab,(10 mg/kg q2 wk),(n=243),E3200(FOLFOX+Bevacizumab):Overall Survival,P r o b a b i l i t y,0.0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,OS(months),0,3,6,9,12,15,18,21,24,27,30,33,36,ALIVE,DEAD,MEDIAN,TOTAL,A:FOLFOX4+bevacizumab,289,246,43,12.9,B:FOLFOX4,290,257,33,10.8,C:bevacizumab,243,216,27,10.2,HR=0.76,A vs B:p=0.0018,B vs C:p=0.95,Bevacizumab with 5-FU/LV:,Overall Survival,Hazard ratio=0.79,Median survival:12.9 vs 16.6 mo(,P,=0.16),20,0,6,30,0,80,100,40,60,24,Months,Percent surviving,5-FU/LV+Avastin(n=104),5-FU/LV+placebo(n=105),18,12,XELOX+placebo,n=350,FOLFOX-4+placebo n=351,XELOX+,bevacizumab,n=350,FOLFOX-4+,bevacizumab,n=349,XELOX n=317,FOLFOX-4,n=317,Initial 2-arm open-label study(n=634),Protocol amended to 2x2 placebo-controlled design after bevacizumab phase III data became available(n=1400),RecruitmentJune 2003 May 2004,RecruitmentFeb 2004 Feb 2005,XELOX-1/NO16966 Trial:Study Design,CRYSTAL:study design,Primary endpoint:PFS,Secondary endpoints:,OS,ORR,safety,FOLFIRI,FOLFIRI+cetuximab,R,First-line mCRC,unresectable(n=1198,),Van Cutsem,et al.NEJM 2009,CRYSTAL:,K-,ras,WT efficacy update,CRYSTAL update,Cetuximab plus FOLFIRI,vs FOLFIRI(n=666),OS,months,23.5,vs 20.0(HR=0.796;p=0.0094),PFS,months,9.9,vs 8.4(HR=0.696;p=0.0012),ORR,%,57.3,vs 39.7(OR=2.0693;p0.0001),Van Cutsem,et,.ECCO-ESMO 2009(abstract No.6077),Lang,et al.,ECCO-ESMO 2009(abstract No.6078),CRYSTAL K-,ras,WT,efficacy,update:significantly longer OS in the cetuximab+FOLFIRI group,Van Cutsem,et al.ECCO-ESMO 2009(abstract no.6077),Probability of overall survival,1.0,0.9,0.8,0.7,0.6,0.5,0.4,0.3,0.2,0.1,0,0,6,12,18,24,30,36,42,48,54,60,Time(months),350,316,311,281,246,237,179,198,132,144,92,108,64,82,48,65,18,21,2,4,0,0,Number of patients:,FOLFIRI,Cetuximab,+FOLFIRI,Cetuximab+FOLFIRI,FOLFIRI,No.of events,Median OS,95%CI,HR(95%):,p-value:,FOLFIRI,(n=350),288,20.0,17.421.7,0.796 0.6700.946,0.0094(log-rank),Cetuximab,+FOLFIRI,(n=316),242,23.5,21.226.3,OPUS:study design,Phase II,Primary endpoint:ORR,Secondary endpoints:,rate of curative metastatic surgery,duration of response,disease control rate,PFS,OS,safety,FOLFOX4,FOLFOX4+cetuximab,R,First-line mCRCunresectable(n=337,),Bokemeyer,et al.JCO 2009,OPUS:,K-,ras,WT,efficacy update,OPUS update,Cetuximab plus FOLFOX4,vs FOLFOX4(n=179),OS,months,22.8,vs 18.5(HR=0.855;p=0.3854),PFS,months,8.3,vs 7.2(HR=0.567;p=0.0064),ORR,%,57.3,vs 34.0(OR=2.5512;p=0.0027),Bokemeyer et al,.ECCO-ESMO 2009(abstract No.6079),PRIME:study design,Primary endpoint:PFS by K-,ras,status,Secondary endpoints:,OS,ORR,duration of response,time to response,safety,Study population,Originally designed to study the overall population,design amended to analyse outcomes with respect to the presence or absence of K-,ras,mutations,tumour K-,ras,status not ascertained in all patients(3 metastases(,P,5 cm(,P,=0.03),Preoperative CT improved survival only in patients with 5 metastases,Adam et al.ASCO,2006.Abstract 3521.,66 patients Liver only mets with CR on CT scan,after Chemotherapy,Surgery,Macroscopic cancer:20,No lesion:46,15 site resected,31 sites left in place,Viable tumor cells:12,In situ recurrence:23,55/66(83%)of Metastases were not cured,Nordlinger JCO2008,Treatment Options&How Long,Cycles,FOLFOX,CR,FOLFOX+Bev,CR,p,Overall,RR,p,18 cycles,38/81,(43%),44/76,(58%),0.00017,57%,0.738,9,12/40,(30%),15/22,(68%),0.0011,55%,Maru DM et al.ASCO GI 2009,abs:295,Cycles,Sinusoidal,Injury,Liver,Insufficiency,18 cycles,26%,4%,9,42%,11%,p,0.017,0.035,Adjuvant,5-FU(Capecitabine)vs.FOLFOX(XELOX),Avastin?,Cetuximab in WT patients?,Goal of Adjuvant Chemotherapy,To eradicate micrometastases,therefore,To increase cure/survival rate after curative surgical resection,Five-year DFS,(%),Five-year OS,(%),5-FU/LEV,12 months,56,63,5-FU/LV(HD),6 months,Roswell Park,59,65,5-FU/LV(LD),6 months,Mayo,60,66,5-FU/LV/LEV,7months,60,67,Number of patients=3759,Standard Adjuvant therapy(1998-2004),(Based on INT 0089),Haller,D.G.et al.J Clin Oncol;23:8671-8678 2005,X-ACT trial in adjuvant treatment of Dukes C colon cancer,1 endpoint:disease-free survival(DFS),2 endpoints,relapse-free survival(RFS),overall survival,tolerability(NCIC CTC),pharmacoeconomics,QoL,Chemo-nave,Dukes C,resection,8 weeks,Capecitabine:,1250mg/m,2,twice daily,d114,q21d,n=1,004,Bolus 5-FU/LV:,5-FU 425mg/m,2,plus LV 20mg/m,2,d15,q28d,n=983,Recruitment,19982001,24 weeks,Confirmed by per protocol analysis,HR 0.89(95%CI 0.76-1.04),Primary endpoint met and trend to superior DFS(ITT),1.0,0.8,0.6,0.4,0123456,Years,Estimated probability,HR=0.87(95%CI:0.751.00)p=0.0528,3-year,Capecitabine(n=1,004)64.2%,5-FU/LV(n=983)60.6%,Phase III MOSAIC,R,FOLFOX4,LV5FU2,(de Gramont),6 months(12 Cycles),Aim:25%decrease in recurrent risk at 3 years,(Expect 3-year DFS:79%vs.73%),2,236 pts,148 Centers,20 Countries,MOSAIC 4-yr DFS:ASCO 2005,1.0,0.9,0.8,0.7,0.6,0.5,0.3,0.4,0.2,0.1,0.0,0,FOLFOX4,LV5FU2,HR 95%CI:,0.75 0.62,0.89,(0.76 0.62-0.92),DFS probability,66,6,12,18,24,30,36,42,48,54,60,Data cut-off:January 16,2005,8.6%,(6.9%),Disease-free Survival in Stage III Patients:N1&N2,DeGramont,A,et al Proc.ASCO GI Jan.2005,66,1.0,0.9,0.8,0.7,0.6,0.5,0.3,0.4,0.2,0.1,0.0,0,FOLFOX4 N1,LV5FU2 N1,FOLFOX4 N2,LV5FU2 N2,Months,DFS,6,12,18,24,30,36,42,48,54,60,7.2%,11.5,%,HR:0.76,HR:0.72,NSABP C-07,FU 500+LV 500,weekly x 6,every 8 weeks x 3,FU 500+LV 500,weekly x 6,every 8 weeks x 3,+,Oxaliplatin 85 weeks 1,3&5,of each 8 week cycle,N=2492,Primary endpoint:,3-year DFS,R,p,0.004,HR:0.79 0.67 0.93,21%Risk Reduction,NSABP C-07 Trial(FLOX vs.FU/LV)3-year Disease-free Survival,0.5,0.6,0.7,0.8,0.9,1,0,1,2,3,4,Ev#3-yr DFS,FLOX 272 76.5%,FU/LV 332 71.6%,NSABP C-07:,t,oxicity and mortality,1.0%,4.7%,1.1%,8.0%,1.2%,2.8%,0,2,4,6,8,10,Gr 3 NCI-sanofi,neurotoxicity,Diarrhea/dehydration,*,Deaths,Percentage of patients,FU/LV,FLOX,*,Diarrhea requiring hospitalization and dehydration due to bowel thickening,0.5%at 12 months,Wolmark,et al,.ASCO 2005;Abstract LBA3500,3-yr DFS,HR,C-07,76.5%,4.9%,0.79,MOSAIC,77.9%,5.1%,0.77,C-07 and MOSAIC 3-yr DFS:Stage II and III,Chemo/radiotherapy-naive,stage III colon,8 weeks since resection,N=1886,Primary endpoint:superiority of DFS,Secondary endpoints:RFS,OS,tolerability,n=944,n=942,RANDO MIS,ATION,Adjuvant XELOX vs 5-FU/LV:NO16968(XELOXA)Phase III trial,Bolus 5-FU/LV,(6 months),Mayo Clinic n=664orRoswell Park n=278,XELOX,(6 months),capecitabine 1000mg/m,2,bid d1,14 oxaliplatin130mg/m,2,d1,q3w8 cycles,Baseline tumour characteristics,XELOX n=944,5-FU/LV Mayo n=664,5-FU/LV Roswell n=278,Primary tumour(%),T1,3,2,6,T2,8,7,8,T3,74,73,76,T4,15,18,9,Regional lymph nodes(%),N1,65,64,67,N2,35,36,33,Number of lymph nodes examined,12,51,50,55,Schmoll et al.,JCO 2007,Diarrhoea,Neutropenia/granulocytopenia,HFS(grade 3),Neurosensorytoxicity,*,Similar rates of grade 3/4 AEs(5%)in all arms,*Not reported,Safety population,Nauseavomiting,0,10,20,30,Patients(%),40,XELOX(n=938),5-FU/LV Mayo(n=657),5-FU/LV Roswell(n=269),Stomatitis,*,Schmoll et al.,JCO 2007,Dose intensity/treatment modifications,*,Ratio dose received vs planned,5-FU/LV(n=926),Mayo(n=657),RP(n=269),XELOX(n=938),Median dose intensity*,85%,87%,84%,Cape 84%Oxal 87%,Reductions,47%,49%,44%,Cape 30%Oxal 35%,Interruptions,15%,8%,32%,Cape 14%Oxal 0%,Delays,37%,42%,26%,Cape 56%Oxal 54%,5-year DFS:,benefit with XELOX maintained and increased over time,XELOX,5-FU/LV,1.0,0.0,0.2,0.4,0.6,0.8,0,1,2,3,4,5,6,Years,ITT population,at 4 years:,6.1%,at 5 years:,6.3%,at 3 years:4.5%,70.9%68.4%,3-yearDFS,66.5%62.3%,4-yearDFS,5-yearDFS,59.8%,66.1%,Years,2,4,6,0.4,0.6,0.8,1.0,0,0.4,0.6,0.8,1.0,Years,8,2,4,6,0,8,Cross-trial comparison of MOSAICand XELOXA:OS in stage III disease,XELOX,5-FU/LV,FOLFOX4,LV5FU2,XELOXA(57 mo),MOSAIC,1,(81.9 mo),ITT population,1.0,0.6,0.8,1.,Andr et al.,JCO,2009,1,2,3,4,5,6,7,8,Cross-trial comparison of MOSAICand XELOXA:OS in stage III disease,Years,XELOX,(n=944),FOLFOX4,(n=672),5-yr OS,6-yr OS,72.9%,77.6%,NO16968(XELOXA)*,MOSAIC,1,*,*,Median observation time:57.0 months,*,Median follow-up:81.9 months,ITT population,0.4,0,NO16968 subgroup analysis of DFS by age,3-year DFS,Hazard ratio,(95%CI),XELOX,5-FU/LV,65 vs.65 years,65 years,n=1142,72%,69%,0.80(0.65,0.98),65 years,n=744,68%,62%,0.81(0.64,1.03),70 vs.70 years,70 years,n=1477,72%,69%,0.79(0.66,0.94),70 years,n=409,66%,60%,0.87(0.63,1.18),ITT population,NO16968 subgroup analysis of OS by age,ITT population,5-year OS,Hazard ratio,(95%CI),XELOX,5-FU/LV,65 vs.65 years,65 years,n=1142,80%,77%,0.87(0.67,1.13),65 years,n=744,73%,70%,0.90(0.68,1.19),70 vs.70 years,70 years,n=1477,80%,76%,0.86(0.69,1.08),70 years,n=409,69%,67%,0.94(0.66,1.34),1.Saltz et al.JCO 2007 2.Van Cutsem et al.JCO,2009;3,.Ychou et al.Ann Oncol,2009,NR=not reported,Trial,DFSHR,DFS (%),p,CALGB 89803,1,NR,NR,0.85,PETACC-3,2,0.90,2.4,0.11,ACCORD-2,3,0.89,3.1,0.44,Irinotecan,combinations:NO survival advantage in stage III,OSHR,OS (%),p,NR,NR,0.74,NR,2.3,0.09,1.09,1,0.69,Irinotecan as Adjuvant setting:,No Benefit,more toxicities,no Role,24 weeks,24 weeks,NSABP C-08:Bevacizumab as Adjuvant Setting,Primary endpoint:DFS at 3 years,Secondary endpoints:survival and tolerability,Patient recruitment completed 10/06,mFOLFOX6 alone,mFOLFOX6+Bevacizumab,5 mg/kg every 2 weeks,Stage III colon cancer,(n=2,710),Bevacizumab,5 mg/kg every 2 weeks,Observation,Ev 3yDFS,mFF6+B,291 77.4,mFF6,312 75.5,HR=0.89,P=0.15,NSABP-08:DFS,%,Yrs,Role of Bevacizumab in Adjuvant Setting:,-Not shown yet,-Should NOT be used,as least right now.,BO17920(AVANT)Phase III Trial,Primary endpoint:DFS at 3 years for stage III,Secondary endpoints:,OS and safety,Accrual completed Q2 2007,Surgery for high risk stage II+stage III colon cancer,(n=3,450),FOLFOX4,FOLFOX4+Avastin,(5 mg/kg every 2 weeks),XELOX+Avastin,(7.5 mg/kg every 3 weeks),Avastin alone,(7.5 mg/kg every 3 weeks),Avastin alone,(7.5 mg/kg every 3 weeks),Observation,Duration of treatment phases,24 weeks,24 weeks,AVANT:patient recruitment timeline,Opened:December 2004,Closed:June 2007,Total accrual:3451 patients,Average monthly accrual:115 patients,Accrual temporarily on hold due to DSMB decision:FebruaryMay 2006,Hoff,et al.ECCO-ESMO 2009(abstract No.6010),AVANT:patient demographics,Hoff,et al.ECCO-ESMO 2009(abstract No.6010),Characteristic,FOLFOX4(n=1151),FOLFOX4+Avastin(n=1155),XELOX+Avastin(n=1145),Disease stage,n(%),II(high risk),III N1,III N2,192(17),585(51)370(32),194(17),590(51)370(32),187(16),572(50)380(33),Male,%,57,51,55,Median age,years,58,58,58,ECOG PS,%01,8614,8614,8614,All
展开阅读全文